Sonnet Other Assets vs Other Current Assets Analysis
| SONN Stock | USD 2.89 0.03 1.03% |
Sonnet Biotherapeutics financial indicator trend analysis is much more than just breaking down Sonnet Biotherapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sonnet Biotherapeutics is a good investment. Please check the relationship between Sonnet Biotherapeutics Other Assets and its Other Current Assets accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonnet Biotherapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Other Assets vs Other Current Assets
Other Assets vs Other Current Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sonnet Biotherapeutics Other Assets account and Other Current Assets. At this time, the significance of the direction appears to have weak relationship.
The correlation between Sonnet Biotherapeutics' Other Assets and Other Current Assets is 0.3. Overlapping area represents the amount of variation of Other Assets that can explain the historical movement of Other Current Assets in the same time period over historical financial statements of Sonnet Biotherapeutics Holdings, assuming nothing else is changed. The correlation between historical values of Sonnet Biotherapeutics' Other Assets and Other Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Assets of Sonnet Biotherapeutics Holdings are associated (or correlated) with its Other Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Assets has no effect on the direction of Other Assets i.e., Sonnet Biotherapeutics' Other Assets and Other Current Assets go up and down completely randomly.
Correlation Coefficient | 0.3 |
| Relationship Direction | Positive |
| Relationship Strength | Very Weak |
Other Assets
Other Current Assets
Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.Most indicators from Sonnet Biotherapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sonnet Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonnet Biotherapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. As of the 22nd of November 2024, Tax Provision is likely to grow to about 69.7 K, while Selling General Administrative is likely to drop about 2.4 M.
Sonnet Biotherapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Sonnet Biotherapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sonnet Biotherapeutics fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 29.8M | 8.0M | 29.0M | 5.8M | 5.4M | 28.3M | |
| Short Long Term Debt Total | 10.3M | 353.3K | 125.9K | 256.0K | 203.9K | 9.8M | |
| Total Current Liabilities | 13.0M | 4.7M | 6.7M | 8.2M | 5.5M | 12.4M | |
| Total Stockholder Equity | 7.4M | 3.0M | 22.3M | (2.5M) | (226.0K) | 8.9M | |
| Property Plant And Equipment Net | 9.8M | 273.8K | 182.3K | 302.8K | 227.1K | 10.2M | |
| Net Debt | 9.8M | (7.0M) | (27.5M) | (2.8M) | (2.1M) | 9.3M | |
| Accounts Payable | 2.4M | 2.1M | 3.8M | 4.8M | 2.2M | 2.3M | |
| Non Current Assets Total | 28.4M | 356.8K | 182.3K | 416.1K | 691.2K | 27.0M | |
| Liabilities And Stockholders Equity | 29.8M | 8.0M | 29.0M | 5.8M | 5.4M | 28.3M | |
| Non Current Liabilities Total | 8.5M | 250.0K | 30.6K | 203.9K | 130.9K | 8.1M | |
| Other Stockholder Equity | 64.1M | 39.7M | 83.9M | 88.9M | 110.0M | 60.9M | |
| Total Liab | 21.5M | 5.0M | 6.7M | 8.4M | 5.7M | 20.5M | |
| Total Current Assets | 1.3M | 7.6M | 28.8M | 5.4M | 4.7M | 1.3M | |
| Short Term Debt | 6.7M | 103.2K | 95.3K | 52.1K | 73.0K | 6.3M | |
| Common Stock | 373.0 | 1.5K | 6.0K | 554.0 | 175.0 | 354.35 | |
| Retained Earnings | (57.1M) | (36.7M) | (61.7M) | (91.4M) | (110.2M) | (60.0M) | |
| Cash | 524.1K | 7.3M | 27.6M | 3.1M | 2.3M | 497.9K | |
| Non Currrent Assets Other | 2.9M | 83.0K | (182.3K) | 113.3K | 464.2K | 2.7M | |
| Cash And Short Term Investments | 524.1K | 7.3M | 27.6M | 3.1M | 2.3M | 497.9K | |
| Other Current Assets | 159.2K | 575.5K | 2.4M | 4.0M | 1.7M | 151.2K | |
| Other Current Liab | 2.8M | 2.1M | 2.3M | 3.2M | 3.2M | 2.7M | |
| Common Stock Shares Outstanding | 439.58 | 30.6K | 79.7K | 197.5K | 1.0M | 417.6 | |
| Property Plant And Equipment Gross | 9.8M | 273.8K | 182.3K | 302.8K | 227.1K | 5.3M | |
| Net Tangible Assets | 7.4M | 3.0M | 22.3M | (2.5M) | 8.5M | 9.0M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonnet Biotherapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.96) | Revenue Per Share 0.019 | Quarterly Revenue Growth (0.50) | Return On Assets (0.97) | Return On Equity (2.65) |
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.